# An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

> **NCT00686582** · PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 304 (actual)

## Conditions studied

- Smallpox

## Interventions

- **BIOLOGICAL:** IMVAMUNE
- **BIOLOGICAL:** IMVAMUNE
- **PROCEDURE:** Blood Draw Only

## Key facts

- **NCT ID:** NCT00686582
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2008-12
- **Final completion:** 2009-06
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2019-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686582, "An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00686582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*